Q1 · MEDICINE
Article
Author: Wang, Tzu-Ming ; Jiang, Yu ; Wu, Guosheng ; Reynen, Paul ; Liederer, Bianca M. ; Volgraf, Matthew ; Fu, Yuhong ; Lu, Aijun ; Pastor, Richard M. ; Scearce-Levie, Kimberly ; Dirksen, Akim ; Yuen, Po-wai ; Hanson, Jesse E. ; Schwarz, Jacob B. ; Plise, Emile ; Luo, Xifeng ; Liu, Mingcui ; Liu, Yanzhou ; Herrington, James ; Wallweber, Heidi J. A. ; Hackos, David ; Tay, Suzanne ; Deshmukh, Gauri ; Zhang, Shun ; Dietz, Matthias G. A. ; Liu, Yichin ; Lupardus, Patrick J. ; Sellers, Benjamin D. ; Gustafson, Amy ; Villemure, Elisia ; Sun, Liang ; Ly, Cuong Q.
The N-methyl-D-aspartate receptor (NMDAR) is a Na(+) and Ca(2+) permeable ionotropic glutamate receptor that is activated by the coagonists glycine and glutamate. NMDARs are critical to synaptic signaling and plasticity, and their dysfunction has been implicated in a number of neurological disorders, including schizophrenia, depression, and Alzheimer's disease. Herein we describe the discovery of potent GluN2A-selective NMDAR positive allosteric modulators (PAMs) starting from a high-throughput screening hit. Using structure-based design, we sought to increase potency at the GluN2A subtype, while improving selectivity against related α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors (AMPARs). The structure-activity relationship of channel deactivation kinetics was studied using a combination of electrophysiology and protein crystallography. Effective incorporation of these strategies resulted in the discovery of GNE-0723 (46), a highly potent and brain penetrant GluN2A-selective NMDAR PAM suitable for in vivo characterization.